Table 1.
In Vitro Activity of Omadacycline and Comparators Against Select Gram-positive Aerobes
| Omadacycline | Tetracycline | Tigecycline | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacteria (No. of Isolates) | MIC50 (μg/mL) | MIC90 (μg/mL) | MIC Range (μg/mL) | % S by CLSIe | MIC50 (μg/mL) | MIC90 (μg/mL) | MIC Range (μg/mL) | % S by CLSI | MIC50 (μg/mL) | MIC90 (μg/mL) | MIC Range (μg/mL) | % S by CLSI |
| S. aureus (4215) | 0.12 | 0.25 | ≤0.015 to 8 | 98.6 | ≤0.5 | ≤0.5 | ≤0.5 to 8 | 94.2 | 0.06 | 0.12 | ≤0.015 to 1 | >99.9 |
| S. aureus MSSA (2777) | 0.12 | 0.25 | ≤0.015 to 1 | 99.9 | ≤0.5 | ≤0.5 | ≤0.5 to 8 | 96.3 | 0.06 | 0.12 | ≤0.015 to 0.25 | 100.0 |
| S. aureus MRSA (1438) | 0.12 | 0.25 | 0.03 to 8 | 96.1 | ≤0.5 | 4 | ≤0.5 to 8 | 90.3 | 0.06 | 0.12 | ≤0.015 to 1 | 99.9 |
| S. aureus TR (221)a | 0.12 | 0.5 | 0.03 to 2 | 95.5 | − | − | − | − | 0.12 | 0.25 | 0.03 to 1 | 99.5 |
| E. faecalis (677) | 0.12 | 0.25 | ≤0.015 to 1 | 97.2 | >16 | >16 | ≤0.12 to 16 | 21.4 | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 |
| E. faecalis VS (663) | 0.12 | 0.25 | ≤0.015 to 1 | 97.1 | >16 | >16 | ≤0.12 to 16 | 21.7 | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 |
| E. faecalis VNS (14) | 0.12 | 0.25 | ≤0.015 to 0.25 | 100.0 | >16 | >16 | 0.25 to 16 | 7.7 | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 |
| E. faecalis TR (524)a | 0.12 | 0.25 | ≤0.015 to 1 | 96.4 | − | − | − | − | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 |
| E. faecium (390) | 0.06 | 0.12 | ≤0.015 to 8 | NA | 16 | >16 | ≤0.12 to 16 | 42.6 | 0.03 | 0.06 | ≤0.015 to 1 | NA |
| E. faecium VS (234) | 0.06 | 0.12 | ≤0.015 to 1 | NA | 0.5 | >16 | ≤0.12 to 16 | 58.1 | 0.03 | 0.06 | ≤0.015 to 0.25 | NA |
| E. faecium VNS (156) | 0.06 | 0.12 | ≤0.015 to 8 | NA | >16 | >16 | ≤0.12 to 16 | 19.2 | 0.03 | 0.06 | ≤0.015 to 1 | NA |
| E. faecium TR (217)a | 0.12 | 0.12 | ≤0.015 to 8 | NA | − | − | − | − | 0.06 | 0.06 | ≤0.015 to 1 | NA |
| S. pneumoniae (1314) | 0.06 | 0.12 | ≤0.015 to 1 | 99.7 | ≤0.25 | >8 | ≤0.25 to 8 | 79.5 | 0.03 | 0.06 | 0.015 to 0.25 | 99.4 |
| S. pneumoniae PS (899) | 0.06 | 0.06 | ≤0.015 to 0.5 | 99.9 | ≤0.25 | 0.5 | ≤0.25 to 8 | 92.2 | 0.03 | 0.06 | 0.015 to 0.12 | 99.4 |
| S. pneumoniae PI (263) | 0.06 | 0.12 | ≤0.015 to 1 | 98.9 | 0.5 | >8 | ≤0.25 to 8 | 59.7 | 0.03 | 0.06 | 0.015 to 0.25 | 98.9 |
| S. pneumoniae PR (152) | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 | >8 | >8 | ≤0.25 to 8 | 38.8 | 0.06 | 0.06 | 0.015 to 0.06 | 100.0 |
| S. pneumoniae MRb (413) | 0.06 | 0.12 | ≤0.015 to 1 | 99.5 | >8 | >8 | ≤0.25 to 8 | 44.1 | 0.06 | 0.06 | 0.015 to 0.25 | 99.5 |
| S. pneumoniae TR (263)a | 0.06 | 0.12 | ≤0.015 to 1 | 99.2 | − | − | − | − | 0.06 | 0.06 | 0.015 to 0.25 | 99.2 |
| S. anginosus group (107) | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 | 0.5 | >8 | ≤0.25 to 8 | 67.3 | 0.03 | 0.03 | ≤0.008 to 0.12 | 100.0 |
| S. anginosus group TR (34)a | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 | − | − | − | − | 0.06 | 0.12 | ≤0.015 to 0.12 | 100.0 |
| β-hemolytic streptococcic (966) | 0.06 | 0.12 | 0.03 to 0.5 | NA | 0.5 | >8 | ≤0.25 to 8 | 54.7 | 0.06 | 0.06 | 0.015 to 0.25 | 100.0 |
| β-hemolytic streptococci TR (421)a | 0.12 | 0.25 | 0.03 to 0.5 | NA | − | − | − | − | 0.06 | 0.06 | 0.015 to 0.25 | 100.0 |
| β-hemolytic streptococci MRd (266) | 0.12 | 0.25 | 0.03 to 0.5 | NA | >8 | >8 | ≤0.25 to 8 | 25.6 | 0.06 | 0.06 | 0.015 to 0.25 | 100.0 |
Adapted from Pfaller et al [13]; isolates were collected in the United States and Europe for the 2016 SENTRY Antimicrobial Surveillance Program.
Abbreviations: % S, percentage susceptible; CLSI, Clinical and Laboratory Standards Institute; E, Enterococcus; MIC, minimum inhibitory concentration; MR, macrolide-resistant; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; NA, data not available; PI, penicillin-intermediate; PR, penicillin-resistant; PS, penicillin-susceptible; S., Staphylococcus; TR, tetracycline-resistant; VNS, vancomycin-nonsusceptible; VS, vancomycin-susceptible.
aIsolates were defined as tetracycline-resistant by CLSI (M100-S27, 2017) breakpoint interpretive criteria; MIC50 and MIC90 data for tetracycline vs these isolates were not calculated.
bIncludes erythromycin- and azithromycin-resistant Streptococcus pneumoniae.
cIncludes Streptococcus agalactiae, Streptococcus canis, Streptococcus dysgalactiae, and Streptococcus pyogenes.
dErythromycin-resistant β-hemolytic streptococci.
eBased on Food and Drug Administration breakpoints (see [18]); the ABSSSI breakpoint was used for Staphylococcus aureus.